OBJECTIVE: to evaluate adult height (AH) in 25 girls with Turner Syndrome (TS), who were treated from before 6 years of age for 10.0 ± 1.7 years with a fixed GH dose of 0.33 mg/kg/week. PATIENTS AND DESIGN: after a 6-month pretreatment assessment all patients were measured 6-monthly under therapy to assess height standard deviation score (H-SDS) and H velocity (HV) until AH achievement. RESULTS: following initial acceleration, HV declined after the first 4 years of therapy. At the end of the 6th year of therapy H-SDS gain was 1.9 ± 1.1. Thereafter, H-SDS gain from baseline decreased, becoming 0.9 ± 0.9 SDS at AH achievement. Bone maturation velocity did not significantly change throughout the prepubertal period. According to Lyon standards for TS, mean AH-SDS was significantly higher than pretreatment H-SDS (p < 0.0001), with a mean H-SDS change of 0.9 ± 0.9. However, the prevalence of patients with AH <-2 SDS (according to Sempé standards) was close to that recorded at start of therapy (16/25 vs 18/25). No significant differences in terms of AH were found between patients with either X monosomy or X-chromosomal abnormalities and between girls with either spontaneous or induced puberty. CONCLUSIONS: we infer that the therapeutic regimen adopted in this prospective study is sufficient to induce a significant growth acceleration during the first years, but the response waned after 6 years of treatment.

Adult height of girls with Turner syndrome treated from before six years of age with a fixed per kg growth hormone dose.

WASNIEWSKA, Malgorzata Gabriela;AVERSA, TOMMASO;DE LUCA, Filippo;LOMBARDO, Fortunato;MESSINA, Maria Francesca;VALENZISE, Mariella
2013-01-01

Abstract

OBJECTIVE: to evaluate adult height (AH) in 25 girls with Turner Syndrome (TS), who were treated from before 6 years of age for 10.0 ± 1.7 years with a fixed GH dose of 0.33 mg/kg/week. PATIENTS AND DESIGN: after a 6-month pretreatment assessment all patients were measured 6-monthly under therapy to assess height standard deviation score (H-SDS) and H velocity (HV) until AH achievement. RESULTS: following initial acceleration, HV declined after the first 4 years of therapy. At the end of the 6th year of therapy H-SDS gain was 1.9 ± 1.1. Thereafter, H-SDS gain from baseline decreased, becoming 0.9 ± 0.9 SDS at AH achievement. Bone maturation velocity did not significantly change throughout the prepubertal period. According to Lyon standards for TS, mean AH-SDS was significantly higher than pretreatment H-SDS (p < 0.0001), with a mean H-SDS change of 0.9 ± 0.9. However, the prevalence of patients with AH <-2 SDS (according to Sempé standards) was close to that recorded at start of therapy (16/25 vs 18/25). No significant differences in terms of AH were found between patients with either X monosomy or X-chromosomal abnormalities and between girls with either spontaneous or induced puberty. CONCLUSIONS: we infer that the therapeutic regimen adopted in this prospective study is sufficient to induce a significant growth acceleration during the first years, but the response waned after 6 years of treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/2579768
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact